Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection

• Kshitij Wagh,

  Affiliation Theoretical Division, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America

  ⨯
• Tanmoy Bhattacharya,

  Affiliations Theoretical Division, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America, Santa Fe Institute, Santa Fe, New Mexico, United States of America

  ⨯
• Carolyn Williamson,

  Affiliation Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town and NHLS, Cape Town, South Africa

  ⨯
• Alex Robles,

  Affiliation Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America

  ⨯
• Madeleine Bayne,

  Affiliation Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America

  ⨯
• Jetta Garrity,

  Affiliation Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America

  ⨯
• Michael Rist,

  Affiliation Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America

  ⨯
• Cecilia Rademeyer,

  Affiliation Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town and NHLS, Cape Town, South Africa

  ⨯
• Hyejin Yoon,

  Affiliation Theoretical Division, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America

  ⨯
• Alan Lapedes,

  Affiliation Theoretical Division, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America

  ⨯
• Hongmei Gao,

  Affiliation Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America

  ⨯
• Kelli Greene,

  Affiliation Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America

  ⨯
• Mark K. Louder,

  Affiliation Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, United States of America

  ⨯
• Rui Kong,

  Affiliation Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, United States of America

  ⨯
• Salim Abdool Karim,

  Affiliations University of KwaZulu-Natal, Durban Department of Immunology and Microbial Science, Durban, South Africa, Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa

  ⨯
• Dennis R. Burton,

  Affiliation The Scripps Research Institute, La Jolla, California, United States of America

  ⨯
• Dan H. Barouch,

  Affiliation Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America

  ⨯
• Michel C. Nussenzweig,

  Affiliation Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, United States of America

  ⨯
• John R. Mascola,

  Affiliation Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, United States of America

  ⨯
• Lynn Morris,

  Affiliations Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa, National Institute for Communicable Diseases (NICD), NHLS, University of the Witwatersrand, Johannesburg, South Africa

  ⨯
• David C. Montefiori,

  Affiliation Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America

  ⨯
• Bette Korber,

  Affiliation Theoretical Division, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America

  ⨯
•  [ ... ],
• Michael S. Seaman

  * E-mail: mseaman@bidmc.harvard.edu

  Affiliation Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America

  ⨯
• [ view all ]
• [ view less ]